Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion within 30 days of day 1 of studyXx_NEWLINE_xXMust be obtained within 14 days prior to registration for protocol therapy: Hemoglobin >= 8.5 g/dLXx_NEWLINE_xXWithin 14 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin >= 9 g/dL within 28 days prior to registrationXx_NEWLINE_xXWithin 28 days prior to registration: Hemoglobin >= 8 g/dLXx_NEWLINE_xXSTEP I: Hemoglobin >= 8 g/dL (obtained within 28 days prior to randomization)Xx_NEWLINE_xXSTEP II: Hemoglobin >= 8 g/dL (within 28 days prior to randomization to Step II)Xx_NEWLINE_xXHemoglobin >= 10 g/dL within 21 days prior to registration; patients must not have had a blood transfusion within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL within 14 days prior to step 2 randomizationXx_NEWLINE_xXHemoglobin > 9 g/dL, obtained within 4 weeks prior to randomizationXx_NEWLINE_xXHemoglobin >= 9 g/dL must be obtained =< 7 days prior to protocol registrationXx_NEWLINE_xXHemoglobin >= 8 g/dL within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL, obtained within 28 days prior to step 2 registrationXx_NEWLINE_xXWithin less than or equal to 14 days prior to registration: Hemoglobin >= 10 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/L within 4 weeks before randomizationXx_NEWLINE_xXObtained within 28 days prior randomization: hemoglobin must be >= 8 g/dLXx_NEWLINE_xXObtained within 28 days prior to registration: Hemoglobin >= 8 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to Step 1 registrationXx_NEWLINE_xXHemoglobin >= 9 g/dl documented within 28 days prior to step 1 registrationXx_NEWLINE_xXHemoglobin > 9 g/dl documented within 28 days prior to step 3 registrationXx_NEWLINE_xXHemoglobin ? 10g/dLXx_NEWLINE_xXHemoglobin >= 10.0 g/dL and no known active bleeding, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXPhase I only: Patients must have mean hemoglobin concentration < 10.0 g/dL of 2 measurements (not influenced by RBC transfusion within 7 days of measurement) and having received < 4 units of RBCs within 8 weeks prior to start of treatment OR,Xx_NEWLINE_xXPreoperative hemoglobin concentration >= 10 mg/dL within 30 days of registrationXx_NEWLINE_xXHemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin ? 8.0 g/dL (4.96 mmol/L)Xx_NEWLINE_xXHemoglobin >= 8g/dl (unsupported)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 8 g/dL) (within 14 days of treatment initiation)Xx_NEWLINE_xXObtained =< 21 days prior to registration: Hemoglobin (Hgb) >= 9.0 g/dL NOTE: Subjects may not have had a transfusion =< 7 days of registrationXx_NEWLINE_xXHemoglobin (Hg) > 9 g/dL (=< 28 days prior to registration)Xx_NEWLINE_xXTotal hemoglobin >= 9 g/dL (may be post-transfusion)Xx_NEWLINE_xXWithin 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (may have been transfused)Xx_NEWLINE_xXHemoglobin > 9 g/dL, transfusion permittedXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (up to 14 days before treatment initiation)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL must be met within 28 days of C1D1Xx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 10 gm/dL (transfusion is allowed to reach minimum level)Xx_NEWLINE_xXWithin 14 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin (Hb)A1c =< 7.0%Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L (without transfusion or growth factor support/erythropoietin [EPO] dependency)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXTotal hemoglobin >= 9 g/dL (which may be post transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL, within 14 days of registrationXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may be supported by erythropoietin) ANDXx_NEWLINE_xXSAFETY RUN-IN: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin ? 8mg/dL (transfusion to reach this level is permitted)Xx_NEWLINE_xXHemoglobin (Hb) > 9 g/dL within 3 weeks prior to study registrationXx_NEWLINE_xXWithin 30 days prior to enrollment: Hemoglobin > 11 gm/dlXx_NEWLINE_xXHemoglobin >= 9 gm/dl, performed within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin concentration >= 8 g/dL (may be transfused)Xx_NEWLINE_xXHemoglobin ?90 g/LXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.Xx_NEWLINE_xXHemoglobin >= 8.0 g/dl (without transfusion within the previous 7 days)Xx_NEWLINE_xXHemoglobin >= 9 g/dL, within 14 days before the first dose of cabozantinibXx_NEWLINE_xXHemoglobin >= 9.0 gr/dLXx_NEWLINE_xXHemoglobin >= 9 g/dl (patients may be transfused to this level)Xx_NEWLINE_xXHemoglobin >= 8.5 g/dl (recommended cutoff subject to judgment of medical oncologist), but cannot be transfusion dependentXx_NEWLINE_xXHemoglobin >= 8.0 gm/dL; transfusion permitted to achieve this levelXx_NEWLINE_xXHemoglobin >= 9 g/dL within 7 days before the first dose of cabozantinibXx_NEWLINE_xXHemoglobin < 9 g/dL (hemoglobin may be supported by transfusion, erythropoietin, or other approved hematopoietic growth factors)Xx_NEWLINE_xXWithin 10 (except as noted) days of planned treatment initiation: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 14 days prior to C1D1: Hemoglobin > 9.0 g/dLXx_NEWLINE_xXHemoglobin ?9.0 grams per deciliter (g/dL);Xx_NEWLINE_xXHemoglobin (Hb) concentration < 8.0 g/dLXx_NEWLINE_xXHemoglobin ?9 grams per deciliter (g/dL)Xx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (5.58 mmol/L)Xx_NEWLINE_xXObtained =< 2 weeks prior to registration: Hemoglobin >= 9 g/dLXx_NEWLINE_xXObtained within 28 days prior to registration: Hemoglobin (Hgb) >= 9 g/dL (without erythrocyte stimulating agent or transfusion within 7 days of screening)Xx_NEWLINE_xXHemoglobin >= 9 g/dL performed within 30 days prior to the date of registration; no transfusions and erythropoietin supplementation permitted within the last 3 monthsXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXWithin 14 days of treatment registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 14 days prior to registration: Hemoglobin >= 10 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL (with or without transfusion support)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dl (may be transfused) within 14 days of enrollment to trialXx_NEWLINE_xXHemoglobin ?8 g/dL (?80 g/L) (superficial tumor dosing only)Xx_NEWLINE_xXHemoglobin >= 10 g/dL, completed within 14 days prior to the date of registrationXx_NEWLINE_xXhemoglobin ? 9 g/dL; subjects requiring transfusion will be eligible to start studyXx_NEWLINE_xXHemoglobin >= 9 gm/dL before starting therapy; eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin ? 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXHemoglobin >= 8 g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within 14 days prior to registration and within 14 days prior to the start of treatmentXx_NEWLINE_xXDocumented within 14 days of registration: Hemoglobin >= 8 g/dL (may be supported)Xx_NEWLINE_xXHemoglobin greater than 9.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level), within 14 days prior to registrationXx_NEWLINE_xXHemoglobin >= 8.0 g/dL at least 3 weeks prior to screening unless attributable to diseaseXx_NEWLINE_xXWithin 28 days of study registration: Hemoglobin >= 8 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL (with or without transfusion support)Xx_NEWLINE_xXObtained =< 35 days prior to registration: hemoglobin >= 8.0g/dLXx_NEWLINE_xXHemoglobin ? 9 g/dL within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL (with or without transfusion support) within 14 days prior to start of protocol therapy.Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9g/dL (women) or >= 11g/dL (men)Xx_NEWLINE_xXHemoglobin <90 g/LXx_NEWLINE_xXHemoglobin >= 8 g/dL (performed within 14 days of treatment initiation)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of treatment initiation)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of study registrationXx_NEWLINE_xXHemoglobin A1c < 7%Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL, obtained =< 14 days prior to registrationXx_NEWLINE_xXPHASE I: Hemoglobin >= 9 gm/dLXx_NEWLINE_xXPHASE IB: Hemoglobin >= 9 gm/dLXx_NEWLINE_xXHemoglobin > 9 g/dL; patients may be transfused or receive erythropoietic treatment to meet this criterionXx_NEWLINE_xXHemoglobin (Hb) value > 9 g/dLXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may be supported by erythropoietin)Xx_NEWLINE_xXHb <70 g/L (<7.0 g/dl) and/or transfusion dependencyXx_NEWLINE_xXHemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)Xx_NEWLINE_xXHemoglobin >= 10 gm/dL (transfusion is allowed to reach minimum level)Xx_NEWLINE_xXHemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-offXx_NEWLINE_xXHemoglobin > 9 g/dL (standard international [SI] units: 90 g/L)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dLXx_NEWLINE_xXHemoglobin >= 10 g/dL without transfusion within 4 days prior to enrollmentXx_NEWLINE_xXPART II: Absolute hemoglobin >= 9.0 gm/dLXx_NEWLINE_xXHemoglobin >= 9.0g/dLXx_NEWLINE_xXHemoglobin ? 9.0g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL, within 16 days of starting therapyXx_NEWLINE_xXHemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-offXx_NEWLINE_xXPerformed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 14 days prior to first dose of protocol-indicated treatment.Xx_NEWLINE_xXTREATMENT WITH SJCAR19: Hemoglobin > 8 g/dl (can be transfused)Xx_NEWLINE_xXHemoglobin >= 9/g/dL (may have been transfused).Xx_NEWLINE_xXHemoglobin >= 8g/dl.Xx_NEWLINE_xXWithin 14 days of the first dose of study drug: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXAt time of registration and within 4 weeks prior to initiating on-protocol treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin > 8.0 g/dl. Subjects may be transfused to reach this cut-off.Xx_NEWLINE_xXHemoglobin >= 10 g/dL with no blood transfusion in the past 28 days, =< 5 days prior to C1D1Xx_NEWLINE_xXHemoglobin (Hgb) >= 9 g/dL (acceptable to reach via transfusion) obtained within 14 days prior to initiating study treatment.Xx_NEWLINE_xXObtained ? 14 days prior to registration: Hemoglobin ? 8.0 g/dLXx_NEWLINE_xXWithin 10 days prior to the start of study treatment: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin > 8.0 g/dl; subjects may be transfused to reach this cut-offXx_NEWLINE_xXAdequate bone marrows, liver and renal function as assessed by the following laboratory requirements. Hemoglobin ?8.0 g/dL (may not be transfused or treated with erythropoietin in preceding week to maintain or exceed this level)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusion to meet eligibility allowed)Xx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin ? 8 g/dL, with or without transfusion supportXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiationXx_NEWLINE_xXWithin 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Hemoglobin >= 9.0 g/dL (transfusion allowed).Xx_NEWLINE_xXHemoglobin >= 8.5 g/dL, performed within 14 days prior to day 1 of protocol therapyXx_NEWLINE_xXWithin 28 days prior to treatment start: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g / dl obtained =< 14 days prior to study initiationXx_NEWLINE_xXSTRATUM A: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the testXx_NEWLINE_xXSTRATUM B: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the testXx_NEWLINE_xXSTRATUM C: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the testXx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependencyXx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration.Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatmentXx_NEWLINE_xXHemoglobin >= 9.0g/dL.Xx_NEWLINE_xXHemoglobin ? 9 g/dL or ? 5.6 mmol/L within 21 days of treatment initiation without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8 g/dL or >= 5.0 mmol/L within 21 days of treatment initiationXx_NEWLINE_xXPerformed within 10 days of treatment initiation: hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin greater than 8.0 g/dl; subjects may be transfused to reach this cut-offXx_NEWLINE_xXHemoglobin: >= 8 g/dL (may be transfused)Xx_NEWLINE_xXShould be performed within 30 days of treatment initiation: hemoglobin ? 8 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXWithin 5 days prior to the start of study treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).Xx_NEWLINE_xXSTUDY TREATMENT: Hemoglobin >= 9.0 g/dL within 14 days prior to the first study treatment.Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)Xx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)Xx_NEWLINE_xXObtained within 14 days prior to randomization/registration: hemoglobin > 9.0 g/dLXx_NEWLINE_xXHemoglobin > 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post transfusion hemolysis is allowedXx_NEWLINE_xXHemoglobin A1C < 6.5%, within 2 weeks of registrationXx_NEWLINE_xXWithin 28 days prior to administration of study treatment: Hemoglobin >= 10 g/dL with no pack red blood cell transfusion in the past 28 daysXx_NEWLINE_xXHemoglobin >= 8.0 g/dl, with or without transfusionXx_NEWLINE_xXHemoglobin ?8 grams per deciliter (g/dL)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 90 days prior to randomizationXx_NEWLINE_xXHemoglobin >= 8 g/dL (may be supported), within 14 days of registration and within 7 days of the start of treatmentXx_NEWLINE_xXHemoglobin (Hb) ? 9Xx_NEWLINE_xXObtained within 28 days prior to the first dose of cabozantinib: hemoglobin >= 9 g/dL.Xx_NEWLINE_xXHemoglobin 9 g/dl or more; (transfusion permitted)Xx_NEWLINE_xXHemoglobin < 9 g/dL at the screening visit at the screening visitXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin level <= 10.0 gram per deciliter (g/dL)Xx_NEWLINE_xXHemoglobin (Hgb) ? 9 g/dL obtained ? 14 days prior to randomization; patient may receive transfusion as neededXx_NEWLINE_xXHemoglobin 9 g/dl or more; (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 10 g/dL obtained =< 14 days prior to registrationXx_NEWLINE_xXObtained within 14 days of the first study treatment: Hemoglobin > 9 g/dLXx_NEWLINE_xXHemoglobin ? 9 g/dL (may have been transfused)Xx_NEWLINE_xXTo be performed within 14 days of treatment initiation: hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin ? 8 g/dL within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin > 8.0 g/dL; subjects may be transfused to reach this cut-offXx_NEWLINE_xXHemoglobin > 8 g/dL (may be supported)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin > 8.0 mg/dL within 14 days of treatment initiationXx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).Xx_NEWLINE_xXHemoglobin > 9.0 g/dL within 14 days of study registrationXx_NEWLINE_xXWithin 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained within 7 days prior to first study treatmentXx_NEWLINE_xXHemoglobin >= 9.0 g/dL independent of transfusion.Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).Xx_NEWLINE_xXWithin 7 days of registration: Hemoglobin >= 9.0 g/gL or >= 5.6 mmol/L, without recent transfusionXx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin > 9.0 g/dL or >= 5.6 mmol/L without transfusion or (EPO) erythropoietin dependency (within 7 days of assessment)Xx_NEWLINE_xXWithin 14 days of the first dose of the study drugs: Hemoglobin >= 9 g/dl (treatment allowed).Xx_NEWLINE_xXHemoglobin >= 9 g/dl (patients may be transfused to this level).Xx_NEWLINE_xXWithin 10 days prior to on-study date: Hemoglobin ? 9 g/dL (or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL but transfusion allowedXx_NEWLINE_xXHemoglobin > 9.0 g/dL within 14 days of registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion or erythropoietin (EPO) dependency within 7 daysXx_NEWLINE_xXWithin 7 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL (unless due to bone marrow infiltration by tumor, in which case hemoglobin >= 8 g/dL is allowed) and no blood transfusions in the 7 days prior to entry.Xx_NEWLINE_xXWithin 28 days prior to enrollment: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9g/dL (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 14 days of study registration. Patients must not be transfused for at least 14 days prior to study entry.Xx_NEWLINE_xXObtained with 21 days of registration: hemoglobin >= 8 g/dLXx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 21 days prior to randomization/registration: Hemoglobin > 9.0 g/dL.Xx_NEWLINE_xXHemoglobin ? 9 g/dL (uncorrected by RBC transfusion)Xx_NEWLINE_xXHemoglobin >= 9g/dLXx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 8.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level)Xx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 14 days of the first study treatment: Hemoglobin > 9 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXWithin 14 days of the first dose of study drug: Hemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level)Xx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L\r\n* Patients cannot have received transfusion or erythropoietin (EPO) within 7 days of the hemoglobin (Hgb) lab testXx_NEWLINE_xXWithin 7 days (+ 3 day window) of enrollment: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXREP ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)Xx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)Xx_NEWLINE_xXHemoglobin >= 9 g/dL, unsupported by transfusions (within 14 days of study registration)Xx_NEWLINE_xXWithin 7 days before the first dose of study treatment: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL results within 7 days before study drug administrationXx_NEWLINE_xXHemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin < 9.0 g/dL (patients may be transfused above this threshold)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin ? 9 g/dL (may have been transfused)Xx_NEWLINE_xXNo more than 14 days prior to registration: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXObtained =< 28 days prior to registration: Hemoglobin >= 9.0 g/dL without transfusion or erythropoietin (EPO) dependency (=< 7 days prior to assessment)Xx_NEWLINE_xXPerformed within 7 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXPerformed within 14 days of treatment initiation: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin ? 9.0 g/dL without transfusion support within 14 days prior to study treatment (erythropoietin or darbepoetin permitted)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (prior transfusion permitted) within 14 days of cycle 1 day 1Xx_NEWLINE_xXHemoglobin > 9.0 g/dl (may be transfused to achieve this level) based on CBC/differential within 14 days prior to Step 2 registrationXx_NEWLINE_xXHemoglobin >= 10.0 g/dL with no blood transfusion within 28 days of starting treatmentXx_NEWLINE_xXWithin 14 days of the first study treatment: Hemoglobin >= 9 g/dL (may have been transfused)Xx_NEWLINE_xXHemoglobin ?9.0 grams per deciliter (g/dL)Xx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiationXx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 8 g/dL (phase Ib) or >= 10 g/dL (for phase II portion)\r\n* For phase Ib portion only: patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day of the erythrocyte transfusionXx_NEWLINE_xXHemoglobin >= 10 g/dL obtained =< 14 days prior to registrationXx_NEWLINE_xXObtained within 14 days prior to enrollment: hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 14 days prior to first doseXx_NEWLINE_xX(For both cohorts A and B): Hemoglobin (Hb) > 9 G/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL, performed within 14 days of protocol registrationXx_NEWLINE_xXHemoglobin ? 9.5 grams/dLXx_NEWLINE_xXHemoglobin (Hb) > 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXHemoglobin >= 9g/dLXx_NEWLINE_xXParticipants with hemoglobin level >= 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteriaXx_NEWLINE_xXParticipants with hemoglobin level < 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteriaXx_NEWLINE_xXHemoglobin level <9.0 gm/LXx_NEWLINE_xXHemoglobin ? 9.5 grams/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL (may have been transfused)Xx_NEWLINE_xXHemoglobin > 9.0 g/dL obtained =< 7 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL (may have been transfused)Xx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 14 days of randomization: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 8 (with or without transfusion)Xx_NEWLINE_xXDetermined within 3 weeks of treatment initiation: Hemoglobin >= 8.0 g/dlXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (within 16 days of enrollment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 gm/dl prior to biopsy (can be transfused)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL obtained =< 14 days prior to registrationXx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (transfusion is allowed to correct anemia).Xx_NEWLINE_xXPerformed within 14 days (+ 3 working days) prior to registration: Hemoglobin > 10 gm/dl (may be reached by transfusion).Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)Xx_NEWLINE_xXHemoglobin >= 8 mg/dL (Note: Transfusion may be used for eligibility outside of 7 days)Xx_NEWLINE_xXHemoglobin >=8 gram per deciliter (g/dL).Xx_NEWLINE_xXHemoglobin >= 10g/dLXx_NEWLINE_xXWithin 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of registrationXx_NEWLINE_xXHemoglobin level >= 8.0 gm/dL on screening complete blood countXx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 28 days prior to study registrationXx_NEWLINE_xXHemoglobin (Hb) > 9.0 g/dL within 7 days prior to enrollment; Note: the use of transfusion or other intervention to achieve Hb >= 9.0 g/dL is acceptableXx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administrationXx_NEWLINE_xXFOR AML ONLY: Obtained =< 14 days prior to registration: Hemoglobin >= 7.5 g/dlXx_NEWLINE_xXFOR TCL ONLY: Obtained =< 14 days prior to registration: Hemoglobin >= 8.5 g/dlXx_NEWLINE_xXHemoglobin >= 9 g/dl (treatment allowed) within 14 days prior to study entryXx_NEWLINE_xXTo be performed within 10 business days prior to day 1: Hemoglobin >= 8.5 g/dLXx_NEWLINE_xXHemoglobin >= 8.0 g/dL, obtained =< 14 days prior to registrationXx_NEWLINE_xXHemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowedXx_NEWLINE_xXHemoglobin (no transfusion within prior 7 days) >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (5.6 mmol/L) obtained =< 14 days prior to registration; NOTE: transfusions are not allowed =< 7 days prior to registrationXx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9/g/dL (may have been transfused)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administrationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 prior to biopsyXx_NEWLINE_xXHemoglobin >= 9.0 g/dL\r\n* Patients may have a transfusion of red blood cells to meet the hemoglobin requirementXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of registration)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusion allowed but must demonstrate stability after transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 10.0 g/dl; use of transfusion or other intervention to achieve this hemoglobin level is acceptableXx_NEWLINE_xXHemoglobin > 8.0 g/dL should be obtained within 21 days prior to enrollmentXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin more or equal than 2 grams/dL below the institutional level of normalXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 10-15 days of treatment initiation)Xx_NEWLINE_xXHemoglobin >= 10 g/dL (no blood transfusion in the 28 days prior to entry [olaparib guidelines])Xx_NEWLINE_xXHemoglobin >= 8 g/dL within 16 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency within 7 days performed within 7 days of treatment initiation performed within 7 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), during screening and on cycle 1, day 1Xx_NEWLINE_xXHemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)Xx_NEWLINE_xXHemoglobin: >= 8 g/dL (may be transfused)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiationXx_NEWLINE_xXHemoglobin ? 8g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 14 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXObtained within 14 days prior to registration; hemoglobin ? 9 g/dlXx_NEWLINE_xXWithin 60 days prior to registration, hematologic minimal values: hemoglobin > 8.0 g/dlXx_NEWLINE_xXHemoglobin (Hb) level < 8 gm/dlXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained =< 14 days prior to randomization: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin: >= 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 90 g/LXx_NEWLINE_xXCompleted within 60 days of surgery: Hemoglobin ? 9.0 g/dLXx_NEWLINE_xXCompleted within 10 days of SBRT treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8.5 g/dL (without the use of growth factors) (within 14 days prior to registration)Xx_NEWLINE_xXHemoglobin >= 9 g/dL\r\n* May receive transfusion to meet this goalXx_NEWLINE_xXHemoglobin >= 9 g/dL\r\n* Note: Patients requiring transfusion to meet the hemoglobin requirement are not eligible for the studyXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL within first 2 weeks prior to first dose of investigational productXx_NEWLINE_xXHemoglobin >= 7 g/dL or >= 5.6 mmol/L within 14 days prior to registrationXx_NEWLINE_xXHemoglobin (Hgb) >= 10 g/dL; eligibility level for hemoglobin may be reached by transfusion, within 14 day prior to registrationXx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin (Hb) > 10.0 g/dL (can be transfused to this level)Xx_NEWLINE_xXHemoglobin < 9.0 gm/dL (SI units gm/L)Xx_NEWLINE_xXHemoglobin of >= 10 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXPHASE I: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeksXx_NEWLINE_xXPHASE II SCLC: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeksXx_NEWLINE_xXmCRPC EXPANSION COHORT: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin < 90 g/LXx_NEWLINE_xXHemoglobin >= 9 g/dL, with or without transfusion support; NOTE: If the patientâ€™s bone marrow biopsy shows greater than or equal to 50% plasma cells, hemoglobin > 8 g/dL (transfusion support or growth factor support is acceptable)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency\r\n(within 7 days of assessment)Xx_NEWLINE_xXPatients must have hemoglobin >= 8.5 g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= 8.5/ul provided that patients have not received growth factors for at least 14 days prior to entering trialXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.58 mmol/L)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin > 10.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)Xx_NEWLINE_xXHemoglobin >= 7.5 g/dL in the presence of bone marrow involvement independent of transfusion and/or growth factors within 3 months prior to enrollmentXx_NEWLINE_xXPerformed 28 days prior to study registration up to the first dose of study drug: hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9 g/dL (may transfuse or use erythropoietin to achieve this level)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9g/dlXx_NEWLINE_xXHemoglobin >= 8.0 g/dl (eligibility level for hemoglobin may be reached by transfusion)Xx_NEWLINE_xXPerformed within 14 days (+3 working days) of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin if anemia attributed to KS, KSHV-MCD, or KICS >= 7 gm/dL, otherwise >= 8 gm/dL (Group II)Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL (in the absence of transfusion within 2 weeks before randomization)Xx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL, which must be stable in the opinion of the investigator without a history of transfusion dependenceXx_NEWLINE_xXPerformed within 14 days of treatment initiation: Hemoglobin >= 8 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin > 9.0 g/dL obtained within 14 days prior to randomization/registrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion dependencyXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphomaXx_NEWLINE_xXWithin 14 days of first dose of study drug administration: Hemoglobin >= 9.0g/dlXx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollmentXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.58 mmol/L)Xx_NEWLINE_xXHemoglobin >= 90 d/L (or >= 9g/dL)Xx_NEWLINE_xXHemoglobin concentration > 8 g/dL (with or without support)Xx_NEWLINE_xXHemoglobin >= 9 g/dL qualifications (transfusion permitted)Xx_NEWLINE_xXHemoglobin > 9 g/dL (untransfused)Xx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Hemoglobin >= 9 gm/dlXx_NEWLINE_xXPerformed within 28 days prior to study registration up to the first dose of study drug: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXhemoglobin greater than or equal to 8.0 grams/deciliter (g/dL) (a hemoglobin less than 8.0 g/dL is acceptable if it is corrected by growth factor or transfusion before starting lenvatinib).Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL without transfusion support within the past 28 days (erythropoietin or darbepoetin permitted)Xx_NEWLINE_xXHemoglobin greater than or equal to 10.0 gm/dL (transfusion independent)Xx_NEWLINE_xXHemoglobin (Hb) >= 6.0 mmol/LXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL with last transfusion at least 14 days before day 1 of study drugXx_NEWLINE_xXHemoglobin greater than 8.0 g/dL (transfusion independent; no transfusion for >= 7 days prior to study enrollment)Xx_NEWLINE_xXHemoglobin < 9.0 g/dL; patients may not be transfused to meet enrollment criteriaXx_NEWLINE_xXPerformed within 10 days of treatment initiation; hemoglobin ? 9 g/dL or ? 5.6 mmol/LXx_NEWLINE_xXHemoglobin > 8 g/dl (may be transfused)Xx_NEWLINE_xXMust be met within 28 days of C1D1: Hemoglobin >= 9.0 g/dlXx_NEWLINE_xXHemoglobin > 8.0 g/dL; may transfuse to meet eligibilityXx_NEWLINE_xXHemoglobin >= 8 g/dL (may be post-transfusion)Xx_NEWLINE_xXWithin 4 days prior to the first dose of cabozantinib: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 8.5 mg/dl obtained within 28 days prior to registrationXx_NEWLINE_xXHemoglobin (Hb) level < 9 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL, obtained within 30 days of study registrationXx_NEWLINE_xXHemoglobin >= 9.0 mg/dL without transfusion in 2 prior weeksXx_NEWLINE_xXHemoglobin >= 9 g/dL (SI units 90 g/L) (in the absence of transfusion within 24 hours prior to dosing)Xx_NEWLINE_xXHemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level) within 14 days of the first dose of study drugXx_NEWLINE_xXHemoglobin (Hb) >= 9.0 g/dL (transfusion independent)Xx_NEWLINE_xXHemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)Xx_NEWLINE_xXHemoglobin >= 9 g/dl (patients may be transfused to this level)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)Xx_NEWLINE_xXHemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)Xx_NEWLINE_xXHemoglobin <9 g/dL (may receive transfusion or erythropoietin to maintain)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL without transfusion if stem cells are not availableXx_NEWLINE_xXHemoglobin > 8.0 gm/dL, transfusion allowedXx_NEWLINE_xXHemoglobin > 8 g/dl (may be transfused)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (after transfusion if required)Xx_NEWLINE_xXHemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 8 g/dL; this value must be obtained within four weeks before protocol entryXx_NEWLINE_xXHemoglobin >= 8.0 g/dl; subjects may be transfused to reach this cut-offXx_NEWLINE_xXHemoglobin >= 10 gm/dL (performed within 14 days prior to registration); eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL (independent of transfusion and/or growth factors within 3 months prior to cycle 1 day 1)Xx_NEWLINE_xXHemoglobin < 90 g/LXx_NEWLINE_xXHemoglobin >= 8.0 g/dL obtained =< 14 days prior to registrationXx_NEWLINE_xXHemoglobin >= 8 g/L, at screeningXx_NEWLINE_xXHemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)Xx_NEWLINE_xXHemoglobin > 8 g/dl (may be transfused)Xx_NEWLINE_xXHemoglobin >= 9 g/dL; continuation of erythropoietin products is permitted; hemoglobin must be stable above 9 g/dL for at least 2 weeks without blood transfusion to maintain hemoglobin levelXx_NEWLINE_xXHemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)Xx_NEWLINE_xXpatients who have a minimum hemoglobin level of 9Xx_NEWLINE_xXHemoglobin >= 9.0 gm/dL (may be a post transfusion value)Xx_NEWLINE_xXHemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or darbepoetin (Aranesp) for 21 daysXx_NEWLINE_xXHemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.Xx_NEWLINE_xXHemoglobin ?9 g/dL, without transfusion support within 7 days preceding the lab assessment.Xx_NEWLINE_xXHemoglobin ? 9 g/dL OR ? 8 g/dL if anemia due to iBCL, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may transfuse to meet this requirement), obtained =<14 days prior to registrationXx_NEWLINE_xXHemoglobin ? 9 g/dL (without transfusion for at least one month)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin level <= 10.0 gram per deciliter (g/dL)Xx_NEWLINE_xXHemoglobin >= 7 g/dL or >= 5.6 mmol/L with transfusion or erythropoietin (EPO) dependencyXx_NEWLINE_xXHemoglobin >= 8.0 grams/dLXx_NEWLINE_xXHemoglobin ? 10g/dlXx_NEWLINE_xXHemoglobin > 8.0 mg/dL (without transfusion in the preceding 7 days)Xx_NEWLINE_xXHemoglobin >= 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed (repeat if more than 3 days before the first dose)Xx_NEWLINE_xXhemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x10^9/L or history of heparin induced thrombocytopenia;Xx_NEWLINE_xXHemoglobin <9g/dLXx_NEWLINE_xXHemoglobin >9.0 g/dL (may be maintained by transfusion)Xx_NEWLINE_xXHemoglobin ?8.0 g/dL with or without transfusion supportXx_NEWLINE_xXHemoglobin >= 8.0 gm/dL (can be transfused)Xx_NEWLINE_xXWithin 14 days prior to randomization: Hemoglobin must be >= 8 g/dLXx_NEWLINE_xXHemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days.Xx_NEWLINE_xXWithin 28 days prior to administration of study treatment: Hemoglobin ? 10.0 g/dL with no blood transfusion in the past 28 daysXx_NEWLINE_xXWithin 14 days of first dose of study drug: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin ? (9.0 g/dL) - patients may be transfused to meet this criterion.Xx_NEWLINE_xXHemoglobin > 8.0 gm/dL, transfusion allowedXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Hemoglobin (Hgb) >= 9.0 g/dL OR >= 5.6 mmol/L without transfusion of erythropoietin (EPO) dependency, within 14 days prior to first dose of pembrolizumabXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Hgb >= 9.0 g/dL OR >= 5.6 mmol/L without transfusion of EPO dependency, within 14 days prior to first dose of pembrolizumabXx_NEWLINE_xXHemoglobin >= 8 g/dL (transfusion allowed)Xx_NEWLINE_xXWithin 14 days of study drug(s) initiation: Hemoglobin (Hgb) >= 10 g/dL with no blood transfusion in the past 14 days.Xx_NEWLINE_xXHemoglobin >= 8.0 gm/dL within 28 days prior to registration.Xx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusion to meet this criterion is allowed)Xx_NEWLINE_xXObtained ? 14 days prior to registration: hemoglobin ? 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 10 g/dL. Eligibility level for hemoglobin may be reached by transfusion.Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL without transfusion and/or growth factors in the 3 months prior to randomizationXx_NEWLINE_xXHemoglobin > 8 g/dL; patients may be transfused to achieve this valueXx_NEWLINE_xXHemoglobin ? 9 g/dL or ? 5.6 mmol/L within 7 days of treatment initiationXx_NEWLINE_xXWithin 14 days prior to first dose of study drug treatment: Hemoglobin >= 9 g/dL without transfusion in the previous weekXx_NEWLINE_xXRENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: hemoglobin ? 9 g/dLXx_NEWLINE_xXBLADDER: Clinical laboratory values at screening: hemoglobin ? 9 g/dLXx_NEWLINE_xXWithin 7 days before the first dose of cabozantinib: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL =< 14 days prior to registrationXx_NEWLINE_xXAll screening labs should be performed within 14 days (+3 working days) of treatment initiation: hemoglobin >= 9 g/dL or >= 5.6 mmol/L;Xx_NEWLINE_xXHemoglobin >= 9 g/dL (Note: no transfusion within 56 days. Ongoing growth factor support is acceptable if on a stable dose for the past 56 days), within 28 days of day 0.Xx_NEWLINE_xXHemoglobin ? 9g/dL or ? 5.6 mmol/LXx_NEWLINE_xXWithin 10 days of treatment initiation: hemoglobin >= 9 g/dl without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of treatment initiationXx_NEWLINE_xXHemoglobin (no transfusion within prior 7 days) >= 9.0 g/dLXx_NEWLINE_xXObtained =< 21 days prior to registration: Hemoglobin > 9.0 g/dLXx_NEWLINE_xXWithin 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXObtained within 28 days prior to registration: Hemoglobin > 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 8.0 g/dL; if patients have a hemoglobin level below 8, blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 8.0 g/dL for 7 days or longerXx_NEWLINE_xXBlood counts performed within 3 weeks prior to starting study therapy must have hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin^3 10g/dLXx_NEWLINE_xXHemoglobin (Hgb) > 9 g/dL (without transfusion or erythropoietin [EPO] dependency within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)Xx_NEWLINE_xXObtained =< 7 days prior to registration: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 8.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion in the preceding 7 daysXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) obtained =< 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 8 gram per deciliter (g/dL).Xx_NEWLINE_xXHemoglobin >= 10 g/dL with no blood transfusion in the past 28 daysXx_NEWLINE_xXWithin 28 days of study registration: Hemoglobin value >= 9 g/dL at the screening visit (independent of blood transfusion and/or growth factors within 3 months prior to registration)Xx_NEWLINE_xXHemoglobin > 9.0 g/dL â€“ unless determined by treating physician to be disease related, obtained =< 7 days prior to registrationXx_NEWLINE_xXHemoglobin >= 8 g/dL or >= 4.96 mmol/LXx_NEWLINE_xXHemoglobin >= 90 g/LXx_NEWLINE_xXPerformed within 14 days prior to study: Hemoglobin > 10 gm/dlXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXHemoglobin > 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 9.0 g/dL for 7 days or longer)Xx_NEWLINE_xXHemoglobin >= 9 gm/dL (transfusion permitted)Xx_NEWLINE_xXTREATMENT: Patients must have >=10.0 g/dL Hb and no blood transfusion in the past 28 days to receive veliparibXx_NEWLINE_xXARM A: obtained =< 14 days prior to registration: \r\n* Hemoglobin >= 10 g/dlXx_NEWLINE_xXARM B: obtained =< 14 days prior to registration: \r\n* Hemoglobin >= 10 g/dlXx_NEWLINE_xXDOSE ESCALATION COHORT: Hemoglobin ? 9 g/dLXx_NEWLINE_xXDOSE EXPANSION COHORT: Hemoglobin ? 9 g/dLXx_NEWLINE_xXHemoglobin >= 90 g/LXx_NEWLINE_xXMeasured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 daysXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (must be >= 7 days after most recent transfusion), obtained =< 14 days prior to registrationXx_NEWLINE_xXWithin 28 days prior to administration of therapy: Hemoglobin >= 10 g/dL with no blood transfusion within 28 days of initiation of therapyXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L; patients with documented marrow involvement may be transfused to this value, performed within 10 days of treatment initiationXx_NEWLINE_xXObtained =< 7 days prior to registration: Hemoglobin >= 8.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin > 8 g/dl (use of transfusion to achieve this is acceptable)Xx_NEWLINE_xXGylcated hemoglobin (HgbA1c) < 7.5%Xx_NEWLINE_xXHemoglobin >= 8 g/dl (may be transfused)Xx_NEWLINE_xXHemoglobin >= 8.0 (may transfuse)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXWithin 14 days of registration: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL or >= 5.6 mmol/L, specimens must be collected within 10 days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeksXx_NEWLINE_xXWithin 30 days prior to treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; transfusions permittedXx_NEWLINE_xXHemoglobin >= 9 g/dL obtained within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXHemoglobin >= 10 g/dL (may be transfused but must be stable without clinical evidence of ongoing blood loss or hemolysis)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)Xx_NEWLINE_xXHemoglobin >= 9 g/dL obtained within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXHemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL obtained within 28 days prior to step 2 re-registrationXx_NEWLINE_xXIf patient will need ribavirin in their regimen then the following inclusion:\r\n* Hemoglobin (Hg) > 12 g/dL for male\r\n* Hg > 11 g/dL for femaleXx_NEWLINE_xXHemoglobin >= 8; transfusion is allowedXx_NEWLINE_xXWithin 14 days of subject registration: Hemoglobin > 9 g/dL (which may be reached by transfusion)Xx_NEWLINE_xXWithin 14 days of subject registration: Hemoglobin (HB)A1c =< 8%Xx_NEWLINE_xXHemoglobin > 9 g/dL (which may be reached by transfusion)Xx_NEWLINE_xXHemoglobin > 11g/dLXx_NEWLINE_xXHemoglobin >= 10.0 g/dL, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXHemoglobin >= 9 g/dl (per manufacturer recommendation)Xx_NEWLINE_xXDONOR: Anemia (hemoglobin [Hb] < 11 gm/dl) or thrombocytopenia (< 100,000/ul)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dl (may be reached by transfusion)Xx_NEWLINE_xXHemoglobin level >= 11.0 g/dlXx_NEWLINE_xXHemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 daysXx_NEWLINE_xXParticipants with hemoglobin level < 8 g/dL, within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteriaXx_NEWLINE_xXObtained within 28 days prior to registration: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL; these results must be obtained within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 11 g/dL within four weeks prior to randomizationXx_NEWLINE_xXHemoglobin < 8 g/dL within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteriaXx_NEWLINE_xXHemoglobin greater than or equal to 9 g/dL; patients may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin level at least 6.5 g/dL at Screening visitXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.58 mmol/L)Xx_NEWLINE_xXHemoglobin >= 10 g/dL be obtained within 42 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dl (may be reached by transfusion)Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Hemoglobin >= 9 grams/dl; these results must be obtained within 28 days prior to registrationXx_NEWLINE_xXFor RCC, urothelial carcinoma, and gastric or GEJ adenocarcinoma, hemoglobin ?8.0 g/dLXx_NEWLINE_xXPerformed within 14 days of patient registration: Hemoglobin > 9 g/dL(which may be reached by transfusion)Xx_NEWLINE_xXREGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dlXx_NEWLINE_xXHemoglobin >= 9.0 g/dl obtained within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL obtained within 28 days prior to RE-TREATMENT registrationXx_NEWLINE_xXHemoglobin ? 9.0 grams/deciliter (g/dL) (can be corrected by growth factor or transfusion) andXx_NEWLINE_xXHemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L)Xx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained =< 21 days prior to registrationXx_NEWLINE_xXPatients must have a serum erythropoietin level documented before randomization and =< 56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time that serum erythropoietin is drawnXx_NEWLINE_xXHemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.Xx_NEWLINE_xXSUB-PROTOCOL AIM A: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >80 g/dL (without transfusion support within 7 days from start of leukapheresis)Xx_NEWLINE_xXHemoglobin ? 9g/dLXx_NEWLINE_xXHemoglobin >10.5 g/dL (without erythropoietin or blood transfusion within the last 2 weeks)Xx_NEWLINE_xXPatients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:\r\n* >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 daysXx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXHemoglobin > 9 g/dL (International System [SI] units: 90 g/L) without transfusion support or growth factors within 10 days of starting INC280Xx_NEWLINE_xXHemoglobin >= 9 gm/dL (may be corrected by transfusion)Xx_NEWLINE_xXHemoglobin >= 90 g/L (patients may be transfused to meet this criterion), obtained within 14 days prior to initiation of study treatmentXx_NEWLINE_xXHemoglobin ? 9 g/dL. This criterion must be met without transfusion.Xx_NEWLINE_xXHemoglobin >8 g/dL. Participants may be transfused to achieve this value. Elevated indirect bilirubin due to post transfusion hemolysis is allowed.Xx_NEWLINE_xXHemoglobin ? 9g/dl (unsupported) for 7 daysXx_NEWLINE_xXB-Hemoglobin ?90 g/LXx_NEWLINE_xXHb < 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screeningXx_NEWLINE_xXHemoglobin >= 9 g/dL within 14 days prior to Step 3 registrationXx_NEWLINE_xXHemoglobin >= 9 g/dL; erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks; hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1 of study drug without blood transfusion to maintain hemoglobin levelXx_NEWLINE_xXHemoglobin >= 8 gm/dL (may be transfused to achieve this level), ANDXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (SI units gm/L)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL obtained =< 7 days prior to registrationXx_NEWLINE_xXWithin 14 days of enrollment: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 14 days prior to day 1 of protocol therapy)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (after transfusion, if necessary) within 4 weeks of pre-registrationXx_NEWLINE_xXHemoglobin ? 8.0 g/dL (4.96 mmol/L)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin (Hb) > 9 gm/lXx_NEWLINE_xXHemoglobin >= 8 gm/dl (untransfused)Xx_NEWLINE_xXPrior to cyclophosphamide and T cell infusions: hematocrit (Hct) =< 24% or hemoglobin (Hb) =< 8 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependencyXx_NEWLINE_xXWithin 14 days prior to registration: hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL continuation of erythropoietin products is permitted obtained =< 7 days prior to randomization; hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin levelXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL (may be supported by erythropoietin); ANDXx_NEWLINE_xXHemoglobin > 9.0 without transfusion support in the past 28 daysXx_NEWLINE_xXHemoglobin >= 9.0 g/L, within 14 days of study registrationXx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatmentXx_NEWLINE_xXHemoglobin A1c =< 9%Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 28 days of treatment initiation, unless otherwise indicatedXx_NEWLINE_xXAbsence of anemia attributed to the plasma cell disorder*: hemoglobin > 10 g/dl or not more than 2 g/dL below the lower limit of normal\r\n* To be determined based on clinical and laboratory assessment by the primary oncologistXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin (Hb) > 9.0 g/dL within 7 days prior to enrollment; note: the use of transfusion or other intervention to achieve Hb >= 9 g/dL is acceptable (within 7 days prior to registration)Xx_NEWLINE_xXPatient must have a hemoglobin >= 9 gm/dl (this may be achieved by transfusion if needed) obtained within 14 days before registration; if a patient receives packed red blood cell transfusion to achieve a hemoglobin level of >= 9 gm/dl, the hemoglobin level needs to be stable (no drop by more than 1 gm/dl from the post-transfusion hemoglobin level) for at least 1 weekXx_NEWLINE_xXHemoglobin >= 8.0 g/dL, performed within 28 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 7.0 gm/dL obtained =< 7 days prior to registrationXx_NEWLINE_xXAnemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value < 100 g/LXx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL without transfusion for 3 weeksXx_NEWLINE_xXHemoglobin > 9.0 g/dL obtained =< 14 days prior to registrationXx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXParticipants with hemoglobin level < 8.0 g/dL, at time of screening; transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluationXx_NEWLINE_xXHemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 14 days prior to registrationXx_NEWLINE_xXWithin 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXPerformed within 28 days of radiation therapy: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (hemoglobin may be supported by transfusion) obtained =<14 days prior to randomizationXx_NEWLINE_xXHemoglobin >= 8 g/dl (can be transfusion dependent)Xx_NEWLINE_xXHemoglobin >= 10 g/dl based on CBC/differential obtained within 21 days prior to study registration (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10 g/dl is acceptable)Xx_NEWLINE_xXHemoglobin >= 9 g/dL OR >= 5.6 mmol/L (labs should be performed within 14 days of treatment initiation)Xx_NEWLINE_xXPatients with a hemoglobin of less than 12%Xx_NEWLINE_xXHemoglobin > 10 gm/dl; eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin >= 8 g/dL (may be post-transfusion)Xx_NEWLINE_xXHemoglobin >=9.0 grams/decilitre(g/dL) (after transfusion if needed)Xx_NEWLINE_xXHemoglobin ? 8 g/dL (may be transfused ? 5 days)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (90 g/L); previous transfusion is allowedXx_NEWLINE_xXHemoglobin >= 9 g/dL (patients may be transfused to meet this requirement)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)Xx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criterion will not be allowedXx_NEWLINE_xXHemoglobin >9 g/dL (Subjects are allowed to be transfused to this level)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (transfusion permitted)Xx_NEWLINE_xXAt least 4 weeks (28 days) prior to registration: Hemoglobin > 8 g/dL (which may be reached by transfusion)Xx_NEWLINE_xXHematocrit (Hct) =< 24% or hemoglobin (Hb) =< 8 g/dLXx_NEWLINE_xXHemoglobin =< 10.0 g/dL for males and =< 9.0 g/dL for females (transfusion allowed to achieve or maintain levels)Xx_NEWLINE_xXHemoglobin ? 8.0 g/dL with or without transfusion supportXx_NEWLINE_xXHemoglobin >= 90 gm/LXx_NEWLINE_xXHemoglobin >= 10g/dLXx_NEWLINE_xXParticipants with hemoglobin level < 8.0 g/dL, at time of screening; transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluationXx_NEWLINE_xXHemoglobin (Hg) >= 8g/dL (unsupported)Xx_NEWLINE_xXHemoglobin ? 8 g/dL (transfusion is permitted to fulfill this criterion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L) (tested within 14 days prior to registration)\r\n* Subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXWithin 30 days prior to initiation of protocol treatment: Hemoglobin >= 9.0 g/dL (after transfusion if required)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dL with no blood transfusion in the past 28 days.Xx_NEWLINE_xXHemoglobin > 9 g/dL (prior transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin > 9.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)Xx_NEWLINE_xXHemoglobin >= 10 gm/dl (may be reached by transfusion)Xx_NEWLINE_xXHemoglobin >= 8 g/dl (transfusion support allowed)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dl (may be reached by transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 9 g/dL (transfusion to this level is allowed)Xx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: hemoglobin >= 9 g/dL within 3 weeks of study entryXx_NEWLINE_xXHemoglobin >= 9 g/dL (it is acceptable to reach this through transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (blood transfusion permitted to attain this value)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXMeasured within 28 days prior to administration of ABT-888: >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 daysXx_NEWLINE_xXHemoglobin (Hb) > 9g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 9.0 g/dL obtained =< 14 days prior to randomizationXx_NEWLINE_xXHemoglobin >= 9 prior to biopsyXx_NEWLINE_xXWithin 14 days prior to registration: Hemoglobin >= 10Xx_NEWLINE_xXHemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 9 g/dl (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 10 gm/dl (eligibility level for hemoglobin may be reached by transfusion)Xx_NEWLINE_xXHemoglobin >= 8.0 g/dl with transfusion supportXx_NEWLINE_xXHemoglobin >= 8.0 g/dL (obtained =< 14 days prior to registration)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (without transfusion within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 gm/mcl (patients may be transfused to meet this requirement)Xx_NEWLINE_xXEXPANSION COHORT ONLY: Hemoglobin >= 9 g/dL; subjects may not have had an RBC transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 8 gm/dL (can be transfused) within two weeks prior to enrollmentXx_NEWLINE_xXHemoglobin >= 8 g/dL; if anemia is present to the extent that the hemoglobin is < 8 g/dL, then correction by transfusion is indicated before entry into this studyXx_NEWLINE_xXHemoglobin: >= 8 g/dL (no transfusions within 7 days) within 30 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (obtained within 14 days prior to the first study treatment [course 1, day 1])Xx_NEWLINE_xXHemoglobin ?8.0 g/dL (?4.96 mmol/L)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained within 14 days prior to first treatmentXx_NEWLINE_xXHemoglobin ? 9 g/dL (uncorrected by RBC transfusion)Xx_NEWLINE_xXHemoglobin (Hgb) >= 8.5 g/dL (transfusion or erythropoietin-like substances not permitted prior to baseline evaluation)Xx_NEWLINE_xXHemoglobin ? 9 g/dL, (? 8 g/dL for subjects who are transfusion dependent)Xx_NEWLINE_xXHemoglobin concentration > 8 g/dL (with or without support)Xx_NEWLINE_xXDONOR: Presence of sickle hemoglobin as demonstrated by appropriate testing such as hemoglobin electrophoresisXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 10 mg/dL (in the absence of transfusion within 24 hours prior to dosing)Xx_NEWLINE_xXHemoglobin ? 9 g/L (?5.6 mmol/L).Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)Xx_NEWLINE_xXHemoglobin >= 8 g/dL (transfusion support allowed)Xx_NEWLINE_xXHemoglobin >= 9.0 mg/mlXx_NEWLINE_xXHemoglobin 9.0 g/dL (transfusion to meet this criterion is permitted)Xx_NEWLINE_xXHemoglobin ?9 g/dL, without the need for transfusion in the 2 weeks prior to screeningXx_NEWLINE_xXHemoglobin ? 9 g/dL, without the need for transfusion in the 2 weeks prior to screeningXx_NEWLINE_xXAnemia (hemoglobin [Hb] < 10 g/L)Xx_NEWLINE_xXHemoglobin: >= 8 g/dL (may be transfused)Xx_NEWLINE_xXHemoglobin >= 9 gm/dL (may be transfused)Xx_NEWLINE_xXDONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%Xx_NEWLINE_xXHemoglobin ? 8.0 g/dL (4.96 mmol/L)Xx_NEWLINE_xXHemoglobin > 8.0 g/dl based upon complete blood count (CBC)/differential obtained within 2 weeks prior to registration on studyXx_NEWLINE_xXHemoglobin >= 9.0 g/deciliter should be obtained with 28 days prior to randomizationXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 7 days of treatment initiationXx_NEWLINE_xXWithin 14 days prior to first study treatment: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXHemoglobin (Hb) >=10.0 gram per deciliter (g/dL) (can be corrected by growth factor or transfusion).Xx_NEWLINE_xXHemoglobin > 9 g/dL, +/- 7 days from date of ICF signingXx_NEWLINE_xXHemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)Xx_NEWLINE_xXHemoglobin >= 10 g/dL (it is acceptable to reach this through transfusion)Xx_NEWLINE_xXThe hemoglobin level must be greater than 9 g/dL; low hemoglobin counts may be corrected with transfusion to achieve eligibility for studyXx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/LXx_NEWLINE_xXCROSSOVER (STEP 2) REGISTRATION: Hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin Â³ 9.0 g/dL within first 2 weeks prior to first dose of MEDI0680 (AMP-514)Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL (in case of transfusion stable for ?14 days prior to treatment start)Xx_NEWLINE_xXHemoglobin ?8 g/dL [transfusion permitted]Xx_NEWLINE_xXHemoglobin (Hb) level < 9 gm/dlXx_NEWLINE_xXHemoglobin ?8 g/dL [transfusion permitted]Xx_NEWLINE_xXHemoglobin >= 10.0 g/dL; note: this level may be reached by transfusionXx_NEWLINE_xXHemoglobin >= 8 g/dL, within 14 days prior to initiation of study drugXx_NEWLINE_xXHemoglobin ? 10g/dLXx_NEWLINE_xXHemoglobin >= 9 g/dL; subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin ? 8 g/dL (80 g/L) within 21 days prior to randomizationXx_NEWLINE_xXPatients must have documented hemoglobin level of 10g/dL or higherXx_NEWLINE_xXHemoglobin >= 9 mg/dl (NOTE: eligibility level for hemoglobin may be reached by transfusion)Xx_NEWLINE_xXHemoglobin > 8 g/dl (may be transfusion dependent)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administrationXx_NEWLINE_xXHemoglobin < 9.0 gm/dL (SI units gm/L)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (SI units 90 g/L)Xx_NEWLINE_xXHemoglobin >= 90 g/LXx_NEWLINE_xXHemoglobin > 9.0 g/dL (no transfusion permitted within 1 week)Xx_NEWLINE_xXHemoglobin (Hb) >= 9 g/dL; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXHemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)Xx_NEWLINE_xXHemoglobin > 7.0 g/dL unless due to marrow involvement by lymphomaXx_NEWLINE_xXAnticipating surgery, history of hypothyroidism, profound anemia (hemoglobin level of < 10 g/dL =< 28 days prior to registration), or clinical depression per physician discretionXx_NEWLINE_xXHemoglobin >= 10 g/dL (allowing transfusion or other intervention to achieve this minimum hemoglobin)Xx_NEWLINE_xXHemoglobin > 8 g/dL (international system [SI] units: 80 g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusionXx_NEWLINE_xXHemoglobin >= 8g/dLXx_NEWLINE_xXPerformed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXHemoglobin >= 9 g/dL within 28 days prior to registrationXx_NEWLINE_xXHemoglobin ?10.0 grams per deciliter (g/dL) (can be corrected by growth factor or transfusion prior to first dose of study drug);Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)Xx_NEWLINE_xXHemoglobin >= 9 g/dL (patients may be transfused to meet this criterion) (obtained within 28 days prior to the first study treatment)Xx_NEWLINE_xXHemoglobin > 8 g/L within 1 week of enrollment in the studyXx_NEWLINE_xXObtained within 14 days prior to initiation of treatment: Hemoglobin >= 8.0 g/ dLXx_NEWLINE_xXHemoglobin of >=10 g/dl within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibilityXx_NEWLINE_xXHemoglobin >= 11.0 g/dL obtained =< 180 days prior to registrationXx_NEWLINE_xXSignificant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than 21%Xx_NEWLINE_xXHemoglobin >= 9.0g/dLXx_NEWLINE_xXActive or unstable metabolic conditions such as brittle diabetes or severe anemia (hemoglobin < 8 g/dl)Xx_NEWLINE_xXHemoglobin >= 9.0 gm/dL (transfusion permitted)Xx_NEWLINE_xXHemoglobin of >= 10 g/dl within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibilityXx_NEWLINE_xXA hemoglobin level < 10g/dlXx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained within 14 days of the first dose of study drugXx_NEWLINE_xXHemoglobin >= 10 g/dL (for Arm L pembrolizumab and Arm M nivolumab and expansion cohorts for all arms, hemoglobin >= 9 g/dLXx_NEWLINE_xXHemoglobin level of >= 8 g/dL within 2 weeks of enrollment; if the patient has not had blood drawn for a hemoglobin level in the previous two weeks, one will be performed to determine eligibility; patients with a hemoglobin level < 9g/dL will be referred for treatment of anemiaXx_NEWLINE_xXHemoglobin level less than or equal to 11.0 g/dL as assessed by the local laboratory; sample obtained within 7 days prior to randomization (retest in screening is acceptable).Xx_NEWLINE_xXHemoglobin > 8 mg/dl; Physician can maintain a patient's hemoglobin with the use of erythropoietin or transfusions (prophylactic use of G-CSF [filgrastim] is not permitted)Xx_NEWLINE_xXHemoglobin > 11.0 g/dL within 28 days prior to registrationXx_NEWLINE_xXHemoglobin >= 9.0 g/dL within 90 days before enrollmentXx_NEWLINE_xXHemoglobin >= 8 g/dL obtained =< 30 days prior to registrationXx_NEWLINE_xXHemoglobin: 7.0-16.1 gm/dLXx_NEWLINE_xXPatients must have hemoglobin level >= 11gm/dl (age adjusted if appropriate) provided by the reference laboratory performing the testXx_NEWLINE_xXHemoglobin >= 10 g/dL or hematocrit >= 30% obtained =< 45 days prior to randomizationXx_NEWLINE_xXHemoglobin >= 9 g/dL, obtained within 14 days prior to treatment startXx_NEWLINE_xXMeasured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dLXx_NEWLINE_xXAnemia, defined as hemoglobin <10 gram per deciliter (g/dL) or >2 g/dL below lower limit of normal or both; transfusion support or concurrent treatment with erythropoietin stimulating agents is not permittedXx_NEWLINE_xXHemoglobin >= 110 g/LXx_NEWLINE_xXWithin 14 days prior to study entry: Hemoglobin > 9 gm/dlXx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment of Hgb), obtained within 14 days prior to C11-AMT PET scanXx_NEWLINE_xXHemoglobin >= 9 g/dL (5.6 mmol/L) (evaluated within 28 days of randomization); subjects may not have had a transfusion within 7 days of screening assessmentXx_NEWLINE_xXHemoglobin >= 90 g/L independent of transfusionXx_NEWLINE_xXHemoglobin >= 8.5 g/dL without transfusion support > 7 days prior to registrationXx_NEWLINE_xXHemoglobin ?9 g/dL(without transfusion support)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL\r\n* Patients may be transfused or receive erythropoietic treatment to meet this criterionXx_NEWLINE_xXHemoglobin >= 7g/dL (transfusion permitted)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL (within 14 days of study registration)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin dependency (=< 7 days prior to registration), obtained =< 30 days prior to registrationXx_NEWLINE_xXHemoglobin >= 8.5 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiationXx_NEWLINE_xXHemoglobin ?9.0 g/dL (may have been transfused)Xx_NEWLINE_xXHemoglobin >= 10 gm/dL, performed within 28 days prior to registrationXx_NEWLINE_xXEligibility level for hemoglobin may be reached by transfusionXx_NEWLINE_xXHemoglobin A1C > 8.5%Xx_NEWLINE_xXHemoglobin > 5.6 mmol/L (9 g/dL) at the screening visitXx_NEWLINE_xXHemoglobin >= 12 mg/dL for men and >= 11 for womenXx_NEWLINE_xXHemoglobin > 100 g/LXx_NEWLINE_xXHemoglobin ?9 g/dL (?90 g/L) Note that transfusions are allowed to meet the required hemoglobin levelXx_NEWLINE_xXPatients must have >= 10.0 g/dL hemoglobin (Hb) and no blood transfusion in the past 28 days to receive veliparibXx_NEWLINE_xXHemoglobin >= 10 g/dL (acceptable to reach this via transfusion)Xx_NEWLINE_xXHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)Xx_NEWLINE_xXHemoglobin >= 10 g/dL (acceptable to reach this via transfusion)Xx_NEWLINE_xX